Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics has announced the completion of a Phase 2a clinical trial at the University of Michigan, exploring the use of oral psilocybin (TRP-8802) with psychotherapy for fibromyalgia treatment, a market potentially worth A$8Bn. The study outcomes, expected to be presented at an upcoming conference, will guide further research into the company’s IV-infused psilocin formulation (TRP-8803) designed to enhance the treatment experience. This formulation may offer a faster onset and more controlled psychedelic experience, positing a potential alternative to traditional pain management methods.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
